The following is a Practice Update interview with Dr Eric Jonasch, Professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. During this interview, Dr Jonasch talks about the upcoming immunotherapy combinations for use in the first-line for the treatment of metastatic renal cell carcinoma (mRCC), as well as the immunotherapy/targeted therapy combinations currently in development. The clinical trials mentioned during Dr Jonasch’s interview were presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) conference held in San Francisco last week.

See Dr Jonasch’s interview on Practice Update here